The United States of America, as Represented by the Secretary, Department of Health and Human Services

Purdue Research Foundation

Vanderbilt University

Centers for Disease Control and Prevention

Anthony Sanchez

Gary J Nabel

Zhi-yong Yang

Nancy J Sullivan

Larry J Anderson

Thomas G Ksiazek

Pierre E Rollin

Cara Carthel Burns

M Steven Oberste

Raymond Campagnoli

William Allan Nix

Paul A Rota

Dean D Erdman

Mark A Pallansch

James A Comer

Suxiang Tong

Cynthia Goldsmith

William J Bellini

Stephan S Monroe

Charles D Humphrey

Sherif R Zaki

Teresa C T Peret

Joseph P Icenogle

Shannon L Emery

Qi Chen

Donald H Rubin

Thomas W Hodge

David A Sanders

Scott A Jeffers

Jeanette Guarner

Richard F Meyer

Byron T Cook

Christopher D Paddock

Michael D Bowen

Wun-Ju Shieh

Michael W Shaw

Natalie J McDonald

The present invention relates generally to viral vaccines and, more specifically, to filovirus vaccines and methods of eliciting an immune response against a filovirus or disease caused by infection with filovirus.

Development of a preventive vaccine for filovirus infection in primates

Pseudotyped retroviruses having viral glycoproteins with modified O glycosylation regions are provided. Also provided are methods for making the pseudotyped retroviruses of the present invention and for using the pseudotyped retroviruses for transduction of target cells. Cells for stably producing the pseudotyped retroviruses or the present invention are also provided.

Pseudotyped retrovirus with modified ebola glycoprotein

Host nucleic acids and host proteins that participate in viral infection, such as human immunodeficiency virus (HIV), influenza A, and Ebola virus, have been identified. Interfering with or disrupting the interaction between a host nucleic acid or host protein and a virus or viral protein confers an inhibition of or resistance to infection. Thus, interfering with such an interaction in a host subject can confer a therapeutic or prophylactic effect against a virus. The sequences identified can be used to identify agents that reduce or inhibit viral infection.

Cell lines and host nucleic acid sequences related to infectious disease

Disclosed herein is a newly isolated human coronavirus (SARS-CoV), the causative agent of severe acute respiratory syndrome (SARS). Also provided are the nucleic acid sequence of the SARS-CoV genome and the amino acid sequences of the SARS-CoV open reading frames, as well as methods of using these molecules to detect a SARS-CoV and detect infections therewith. Immune stimulatory compositions are also provided, along with methods of their use.

Coronavirus isolated from humans

The present invention relates generally to viral vaccines and, more particularly, to filovirus vaccines and methods of eliciting an immune response against a filovirus or disease caused by infection with filovirus.

Ebola virus vaccines comprising nucleic acid molecules encoding Ebola viral proteins are provided. In one embodiment, the nucleic acid molecule encodes the transmembrane form of the viral glycoprotein (GP). In another embodiment, the nucleic acid molecule encodes the secreted form of the viral glycoprotein (sGP). In yet another embodiment, the nucleic acid molecule encodes the viral nucleoprotein (NP). Methods for immunizing a subject against disease caused by infection with Ebola virus are also provided.

Immunization for ebola virus infection

Growing community of inventors

Lilburn, GA, United States of America

Anthony Sanchez